Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI‐74330, using a murine CXCR3 internalization assay
Open Access
- 1 December 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (8) , 1260-1271
- https://doi.org/10.1038/sj.bjp.0707519
Abstract
Background and purpose: Pharmacokinetic/pharmacodynamic (PK/PD) models are necessary to relate the degree of drug exposure in vivo to target blockade and pharmacological efficacy. This manuscript describes a murine agonist‐induced CXCR3 receptor internalization assay and demonstrates its utility for PK/PD analyses.Experimental approach: Activated murine DO11.10 cells were incubated with agonist in the presence or absence of a CXCR3 antagonist and changes in surface CXCR3 expression were detected by flow cytometry. For PK/PD analysis, mice were dosed with a small molecule CXCR3 antagonist, NBI‐74330, (100 mg kg−1) orally or subcutaneously and plasma samples taken at specified timepoints for the CXCR3 internalization assay.Key results: Surface CXCR3 expression was specifically decreased in response to CXCL9, CXCL10 and CXCL11. CXCL11 was the most potent CXCR3 agonist in buffer (pA50=9.23±0.26) and the pA50 for CXCL11 was unaltered in murine plasma (pA50=9.17±0.15). The affinity of a small molecule CXCR3 antagonist, NBI‐74330, was obtained in the absence or presence of plasma (buffer pA2 value: 7.84±0.14; plasma pKB value 6.36±0.01). Administration of NBI‐74330 to mice resulted in the formation of an N‐oxide metabolite, also an antagonist of CXCR3. Both antagonists were detectable up to 7 h post oral dose and 24 h post subcutaneous dose. Measurement of CXCR3 internalization demonstrated significant antagonism of this response ex vivo, 24 h following subcutaneous administration of NBI‐74330.Conclusions and implications: The CXCR3 receptor internalization assay provides a robust method for determining agonist potency orders, antagonist affinity estimates and PK/PD analyses, which discriminate between dosing regimens for the CXCR3 antagonist NBI‐74330.British Journal of Pharmacology (2007) 152, 1260–1271; doi:10.1038/sj.bjp.0707519; published online 5 November 2007Keywords
This publication has 53 references indexed in Scilit:
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentBritish Journal of Clinical Pharmacology, 2004
- Efficient T-Cell Surveillance of the CNS Requires Expression of the CXC Chemokine Receptor 3Journal of Neuroscience, 2004
- Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi‐step model of ligand binding and receptor activationEuropean Journal of Immunology, 2003
- CXCR3 and Heparin Binding Sites of the Chemokine IP-10 (CXCL10)Journal of Biological Chemistry, 2003
- Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its LigandsJournal of Biological Chemistry, 2003
- Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localizationEuropean Journal of Immunology, 1998
- Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor modelTrends in Pharmacological Sciences, 1994
- Synthesis of 4-amino-1H-pyrrolo[2,3-b]pyridine (1,7-dideazaadenine) and 1H-pyrrolo[2,3-b]pyridin-4-ol (1,7-dideazahypoxanthine)The Journal of Organic Chemistry, 1980
- The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptorsProceedings of the Royal Society of London. B. Biological Sciences, 1965